Study Supported by NIH Funding

NEW YORK, NY / ACCESSWIRE / May 20, 2016 / Islet Sciences, Inc. (OTC: ISLT) ("Islet Sciences"), a biopharmaceutical company focused on developing new technologies and medicines for the early detection, intervention and pre-treatment to prevent and slow the progression of metabolic disease, today announced Islet Sciences' MDNA diagnostic tools for early detection of insulin dependent diabetes were used in a multi-center clinical study. Results of the study were published in Herold K, et al. β Cell death and dysfunction during type 1 diabetes development in at risk individuals. J. Clinical Invest. 2015 Mar 2: 125(3): 1163-1173. doi 10.1172/JCI78142. The study was supported by funding from the National Institutes of Health (NIH), the Juvenile Diabetes Research Foundation (JDRF), and the American Diabetes Association.

The study set out to measure the primary pathologic process of type 1 diabetes (T1D). Clinicians measured β cell death with an assay that detects β cell-derived unmethylated insulin (INS) DNA. Using the assay, the researchers performed an observational study of 50 participants from 2 cohorts at risk for developing T1D from the TrialNet Pathway to Prevention study and 4 subjects received Islet Autotransplants. The study concluded that a blood test that measures unmethylated INS DNA serves as a market of active β cell killing as the result of T1D-associated autoimmunity. Together, the data support the concept that β cell killing occurs sporadically during the years prior to diagnosis of T1D and is more intense in the peridiagnosis period.

John Steel, Director of Islet Sciences stated, "We are pleased and excited that Islet Sciences MDNA diagnostic for early detection of insulin dependent diabetes continue to be a key component in critical diabetes research. At Islet Sciences, our goal is to continue producing state-of-the-art technologies that will improve the lives of those suffering from diabetes and other life-threatening conditions."

About Islet Sciences:

Islet Sciences, Inc., a biopharmaceutical company based in Yorba Linda, CA, is developing new medicines and technologies for the treatment of metabolic disease. For more information, please visit http://www.isletsciences.com.

Forward-Looking Statements:

Certain statements in this press release constitute forward-looking statements. These statements are not historical facts but instead represent only Islet Science's belief regarding future events, many of which, by their nature, are inherently uncertain and outside Islet Science's control. It is possible that actual results will differ, possibly materially, from the anticipated results indicated in these statements. Factors that could affect Islet Science's financial and other results are included in Islet Sciences' periodic filings with the SEC pursuant to the Securities Exchange Act of 1934.

Contact:

Islet Sciences

John Steel, Director

Phone: + 1 858-692-7897

SOURCE: Islet Sciences, Inc.